Dr. Emily Seto discusses her work in the emerging field of mHealth (mobile health) and how mobile technologies such as health apps and wearables can be used in healthcare.

In part 1 of this Exclusive Interview, Dr. Emily Seto talks with Diabetes in Control Publisher Steve Freed during the ADIn part 1 of this Exclusive Interview, Dr. Emily Seto talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the focus on mobile technology in the area of healthcare management.A meeting in San Diego, CA about the focus on mobile technology in the area of healthcare management.

In part 2 of this Exclusive Interview, Dr. Emily Seto talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the apps in development and their impact on improving diabetes management.

In part 3 of this Exclusive Interview, Dr. Emily Seto talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the challenges within the patient use of technology.

In part 4 of this Exclusive Interview, Dr. Emily Seto talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the future of mobile health technology and coming up with new ideas.

In part 5 of this Exclusive Interview, Dr. Emily Seto talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the development of mobile health technology.

Now that we are in the new year our patients will have every good intention on changing everything to make this their best and healthiest year ever. They will try a new exercise program and a new diet. They will swear they will take their medications and fix their glucose, …

In part 1 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, California about his work targeting PCSK9 with RNA interference to see how that impacts on lipids and clinical outcomes.

In this week's Homerun Slides, personalized treatment according to a patient's B-cell classification and common etiological factors that can be found at work across all diabetes sub-types.

The role of statins in the primary and secondary prevention of CVD has been well established. Patients with NAFLD are believed to have increased cardiovascular risk and are logical candidates for their long-term use. In accordance with their higher cardiovascular risk, the use of statins should be encouraged in patients with NAFLD but their use has remained controversial in such patients, particularly in the setting of elevated liver enzymes. Recent practice guidelines on statin use in patients with NAFLD have clearly established that they are overall safe and that they do not carry a higher risk of liver toxicity.